Overview

* Beam Therapeutics ( BEAM ) Q3 net loss misses analyst expectations

* Company ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028

* Beam progressing with BEAM-302 and BEAM-101 clinical trials

Outlook

* Beam expects to report BEAM-302 trial data in early 2026

* Company plans to present BEACON trial data at ASH meeting in December 2025

* Beam's cash runway expected to support operations into 2028

Result Drivers

* CASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028

* R&D EXPENSES - Increased R&D expenses to $109.8 mln in Q3 2025, contributing to net loss

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $9.69

License mln

and

Collabor

ation

Revenue

Q3 Net Miss -$112.72 -$96.50

Income mln mln (11

Analysts

)

Q3 Miss -$126.81 -$107

Operatin mln mln (11

g Income Analysts

)

Q3 Miss -$112.72 -$105.50

Pretax mln mln (9

Profit Analysts

)

Q3 $136.50

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Beam Therapeutics Inc ( BEAM ) is $42.50, about 42.9% above its November 3 closing price of $24.25

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)